一项评价Tafasitamab和来那度胺联合吉西他滨和奥沙利铂对比利妥昔单抗联合吉西他滨和奥沙利铂治疗复发/难治性弥漫性大B细胞淋巴瘤患者的有效性和安全性的随机、多中心、III期临床研究
[Translation] A randomized, multicenter, phase III clinical study to evaluate the efficacy and safety of tafasitamab and lenalidomide combined with gemcitabine and oxaliplatin versus rituximab combined with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma
评价Tafasitamab和来那度胺联合GemOx治疗复发/难治弥漫大B淋巴瘤患者的安全耐受性,以及与R-GemOx对比在复发/难治弥漫大B淋巴瘤患者中的有效性及安全性
[Translation] To evaluate the safety and tolerability of Tafasitamab and Lenalidomide combined with GemOx in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma, and to compare the efficacy and safety of Tafasitamab and Lenalidomide combined with GemOx in patients with relapsed/refractory diffuse large B-cell lymphoma
100 Clinical Results associated with Incyte Biosciences Technical Operations SARL
0 Patents (Medical) associated with Incyte Biosciences Technical Operations SARL
100 Deals associated with Incyte Biosciences Technical Operations SARL
100 Translational Medicine associated with Incyte Biosciences Technical Operations SARL